\
&
Contact us
\
&
Contact us
This was 5 years ago
Location ProgrammesAn information session on the Marie Skłodowska-Curie Actions (MSCA) 2020 call for proposals for the Research and Innovation Staff Exchange (RISE) was organised by the Belgian Science Policy Office (BELSPO), the Fund for Scientific Research – FNRS (F.R.S.-FNRS) and NCP Flanders.
The information session was organised to support researchers/research organisations/industry in the preparation of their MSCA RISE application.
RISE funds short-term exchanges for staff to develop careers combining scientific excellence with exposure to other countries and sectors. RISE enables more interaction between academia and non-academic organisations within Europe and worldwide.
Participation to the session was free and open to any researcher wishing to apply with a Belgian Host Institution, or any staff member of a Belgian Host Institution. Registration was mandatory.
The presentations are available on the event website and below.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
